FY2024 Earnings Estimate for BioSyent Issued By Bloom Burton

BioSyent Inc. (CVE:RX) – Analysts at Bloom Burton raised their FY2024 earnings per share estimates for shares of BioSyent in a research note issued on Thursday, November 21st. Bloom Burton analyst D. Martin now anticipates that the company will earn $0.63 per share for the year, up from their previous estimate of $0.59. The consensus estimate for BioSyent’s current full-year earnings is $0.69 per share. Bloom Burton also issued estimates for BioSyent’s FY2025 earnings at $0.80 EPS and FY2026 earnings at $0.91 EPS.

BioSyent Price Performance

Shares of CVE:RX opened at C$11.70 on Monday. The business has a fifty day moving average price of C$11.05 and a 200-day moving average price of C$10.27. The company has a debt-to-equity ratio of 3.19, a current ratio of 6.13 and a quick ratio of 6.91. The company has a market capitalization of C$135.60 million, a PE ratio of 19.50 and a beta of 0.93. BioSyent has a 1-year low of C$8.24 and a 1-year high of C$11.74.

BioSyent (CVE:RX) last issued its quarterly earnings results on Monday, August 26th. The company reported C$0.13 EPS for the quarter, hitting analysts’ consensus estimates of C$0.13. The firm had revenue of C$8.95 million for the quarter, compared to analysts’ expectations of C$8.80 million. BioSyent had a return on equity of 20.88% and a net margin of 21.14%.

Insider Buying and Selling

In related news, Director Seyed Ahmad Ashrafi sold 2,320 shares of the company’s stock in a transaction on Friday, September 20th. The stock was sold at an average price of C$10.95, for a total transaction of C$25,404.00. Also, insider FAX Capital Corp. sold 230,800 shares of the stock in a transaction dated Friday, November 22nd. The shares were sold at an average price of C$11.12, for a total value of C$2,566,496.00. In the last ninety days, insiders sold 233,720 shares of company stock worth $2,598,560. 33.65% of the stock is owned by corporate insiders.

About BioSyent

BioSyent Inc, together with its subsidiaries, acquires or licenses, develops, and sells pharmaceutical and other healthcare products in Canada and internationally. Its products include FeraMAX Pd Therapeutic 150 for the treatment of iron deficiency anemia; FeraMAX Pd Maintenance 45, a chewable supplement for the prevention of iron deficiency anemia; and FeraMAX Pd Powder 15, a powder form product used for preventing iron deficiency and iron deficiency anemia.